Cholestatic liver disease
- Page Path
-
- HOME
- TOPICS
- Cholestatic liver disease
- Reply to Correspondence
- Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”
- Byoung Kuk Jang
- Clin Mol Hepatol. 2024;30(2):297-298. Published online April 1, 2024
-
View: 2653 Download: 47
- Correspondence
- Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances
- Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu
- Clin Mol Hepatol. 2024;30(2):279-280. Published online March 20, 2024
-
View: 2981 Download: 72 Web of Science: 1 Crossref: 1
- Original Article
- JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis
- Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu
- Clin Mol Hepatol. 2024;30(2):206-224. Published online January 8, 2024
-
View: 6275 Download: 265 Web of Science: 5 Crossref: 5
- Editorial
- JCAD, a new potential therapeutic target in cholestatic liver disease
- Byoung Kuk Jang
- Clin Mol Hepatol. 2024;30(2):166-167. Published online March 8, 2024
-
View: 3322 Download: 82 Web of Science: 1 Crossref: 1
- Original Article
- Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
- Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun
- Clin Mol Hepatol. 2023;29(2):465-481. Published online February 20, 2023
-
View: 8583 Download: 332 Web of Science: 25 Crossref: 26
- Letter to the Editor
- Macro-aspartate aminotransferase in a healthy woman
- Maria Lorubbio, Agostino Ognibene, Benedetta Salvadori, Alessandra Fanelli, Giacomo Laffi
- Clin Mol Hepatol. 2020;26(3):378-381. Published online June 23, 2020
-
View: 6613 Download: 149 Web of Science: 3 Crossref: 3
- Original Article
- Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years
- Young Chang, Jun Il Kim, Bora Lee, Sang Gyune Kim, Min Jung Jung, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Jeong-Ju Yoo
- Clin Mol Hepatol. 2020;26(3):318-327. Published online May 25, 2020
-
View: 7702 Download: 268 Web of Science: 26 Crossref: 26
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
Video abstract
-
- Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
- Modulation of lymphatic vessels in management of liver disease and complications
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
- Examining the therapeutic landscape of beta-blockers in portal hypertension
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor16.9First decision
07 Days
Publication after acceptance
04 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2023-2025)
|
|||||||
